Cost-Effectiveness Analysis of Lamivudine for the Treatment of Chronic Hepatitis B

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.17, Iss.5, 2000-05, pp. : 409-427

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost-Effectiveness Analysis of Prophylactic Lamivudine Use in Preventing Vertical Transmission of Hepatitis B Virus Infection

By Hung Hui-Fang

PharmacoEconomics, Vol. 29, Iss. 12, 2011-12 ,pp. : 1063-1073

Adis International

Access to resources Recommend Favorite

Lamivudine for the treatment of chronic hepatitis B

By Sokal Etienne

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 3, 2002-03 ,pp. : 329-339

Informa Healthcare

Access to resources Recommend Favorite

Cost Effectiveness of Entecavir versus Lamivudine with Adefovir Salvage in HBeAg-Positive Chronic Hepatitis B

By Veenstra David L.

PharmacoEconomics, Vol. 25, Iss. 11, 2007-01 ,pp. : 963-977

Adis International

Access to resources Recommend Favorite

A Cost-Effectiveness Analysis of Currently Approved Treatments for HBeAg-Positive Chronic Hepatitis B

By Spackman D. Eldon Veenstra David L.

PharmacoEconomics, Vol. 26, Iss. 11, 2008-01 ,pp. : 937-949

Adis International

Access to resources Recommend Favorite

Cost-Effectiveness of Nucleoside Analog Therapy for Hepatitis B in China: A Markov Analysis

By Wu Bin Li Te Chen Huafeng Shen Jinfang

Value in Health, Vol. 13, Iss. 5, 2010-08 ,pp. : 592-600

Blackwell Publishing

Access to resources Recommend Favorite